Calamos Wealth Management LLC bought a new position in Astrazeneca Plc (NYSE:AZN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 31,549 shares of the company's stock, valued at approximately $2,900,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its stake in Astrazeneca by 1.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 135,636 shares of the company's stock worth $12,469,000 after buying an additional 2,056 shares in the last quarter. Lebenthal Global Advisors LLC purchased a new stake in Astrazeneca in the fourth quarter worth approximately $1,221,000. Cora Capital Advisors LLC boosted its stake in Astrazeneca by 9.9% in the fourth quarter. Cora Capital Advisors LLC now owns 4,370 shares of the company's stock worth $402,000 after buying an additional 394 shares in the last quarter. Diversified Enterprises LLC boosted its stake in Astrazeneca by 28.8% in the fourth quarter. Diversified Enterprises LLC now owns 9,019 shares of the company's stock worth $829,000 after buying an additional 2,015 shares in the last quarter. Finally, WPG Advisers LLC boosted its stake in Astrazeneca by 6.2% in the fourth quarter. WPG Advisers LLC now owns 2,177 shares of the company's stock worth $200,000 after buying an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
Astrazeneca Trading Down 1.3%
Shares of AZN stock opened at $189.71 on Friday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a fifty-two week low of $132.32 and a fifty-two week high of $212.71. The company has a market capitalization of $294.22 billion, a price-to-earnings ratio of 32.68, a P/E/G ratio of 1.45 and a beta of 0.35.
Astrazeneca Dividend Announcement
The business also recently disclosed a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca's payout ratio is presently 74.83%.
Analysts Set New Price Targets
AZN has been the subject of several research reports. TD Cowen reaffirmed a "buy" rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Wall Street Zen lowered Astrazeneca from a "buy" rating to a "hold" rating in a research note on Saturday, April 4th. Citigroup initiated coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a "buy" rating for the company. Barclays reaffirmed an "overweight" rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Astrazeneca in a research note on Friday, February 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $102.67.
Read Our Latest Research Report on Astrazeneca
Astrazeneca Company Profile
(
Free Report)
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrazeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrazeneca wasn't on the list.
While Astrazeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
